AlphaYou
Overview
No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.
Key stats
Aug 17- Open
- $260.65
- 52-wk high
- $274.90
- High
- $261.71
- 52-wk low
- $170.33
- Low
- $259.16
- Prev close
- $260.35
Smart money
Earnings
Reported Jul 15, 2026
Earnings came in 2.1% above what analysts expected.
Financials
Sep 2025 to Jun 2026
What it sold, what it cost, what was left.
Sep 2025Dec 2025Mar 2026Jun 2026
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| RevenueTotal revenue | $23.99B | $24.56B | $24.06B | $25.31B |
| Cost of what it soldCost of revenue | $7.30B | $7.97B | $6.86B | $6.81B |
| Gross profit | $16.69B | $16.60B | $17.20B | $18.50B |
| What it spent | ||||
| Research and development | $3.67B | $4.25B | $3.53B | $3.65B |
| Sales and adminSelling, general and administrative | $5.92B | $6.95B | $6.03B | $6.43B |
| Other operating costsOperating costs not itemised in the filing's summary | — | -$200.0M | $1.25B | $1.25B |
| Total operating expenses | $9.59B | $11.01B | $10.81B | $11.33B |
| What was left | ||||
| Operating profitOperating income | $7.10B | $5.59B | $6.39B | $7.17B |
| Interest on debtInterest expense | $245.0M | $214.0M | $272.0M | $281.0M |
| Profit before tax | $7.49B | $4.97B | $5.99B | $6.75B |
| TaxIncome tax expense | $2.34B | -$150.0M | $755.0M | $1.21B |
| Net profitNet income | $5.15B | $5.12B | $5.24B | $5.53B |
| EBITDAEarnings before interest, tax, depreciation, amortisation | $9.29B | $7.19B | $8.27B | $8.99B |
Technicals
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
85 / 100
RSI 14
40balanced
20D volatility
20%annualized
52-week range
$260.35$170.33$274.90
20D support
News
News
What the news says
50 articles · 7 days
Coverage is bullish
26 bullish · 22 neutral · 2 bearish
Tone of tracked coverage
Johnson & Johnson Purchases New Shares in Xencor, Inc. $XNCR
Leans bullishAug 16Johnson & Johnson Makes New $9.12 Billion Investment in Fate Therapeutics, Inc. $FATE
NeutralAug 161,849,445 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by Johnson & Johnson
NeutralAug 16
